4.0
CRISPR Therapeutics AG operates in the healthcare sector, within the biotechnology subsector focused on the development of gene therapies based on genome editing. The company’s shares are traded on the Nasdaq under the ticker CRSP and it was founded by researchers associated with the scientific advancement of CRISPR-Cas9 technology, notably Emmanuelle Charpentier and academic collaborators engaged in molecular genetics research.
The company was established in the private sector, with no direct government affiliation, driven by the commercial and therapeutic application of scientific discoveries related to precise DNA editing. Its initial objective centered on the development of innovative treatments for rare genetic diseases, hematological conditions, and disorders of high clinical complexity.
Core products and services consist of gene therapies in clinical development, based on both ex vivo and in vivo genome editing approaches. The portfolio includes programs targeting blood disorders, oncology, immunotherapy, and metabolic diseases, as well as proprietary technology platforms for biotechnology research and development.
The company’s market presence is international, with a primary focus on the United States and Europe. Activities include collaboration with clinical centers, university hospitals, and strategic partners in countries such as the United States, Germany, Switzerland, and the United Kingdom, alongside operations in leading global biomedical research hubs.
Relevant market factors include the evolution of regulatory frameworks for advanced therapies, competition from other gene-editing and biotechnology companies, high research and development costs, reliance on clinical trial outcomes, and growing demand for personalized and precision-based treatments.
Operational scale is consistent with late-stage clinical biotechnology companies, involving hundreds of highly qualified employees, multiple programs under development, and strategic partnerships with global pharmaceutical companies. Operations are not directed toward direct service provision to end consumers.
The operational structure comprises a corporate headquarters in Zug, Switzerland, research and development centers in the United States and Europe, and units dedicated to clinical operations, regulatory affairs, outsourced manufacturing, and intellectual property management. The business model is highly research-intensive and based on institutional collaboration.
The primary trading ticker is CRSP, listed on the Nasdaq, representing the company’s common shares in the U.S. equity market.
History and foundation
The company was founded in 2013 in Switzerland, with the establishment of CRISPR Therapeutics AG as an organization dedicated to translating academic discoveries into therapeutic solutions based on CRISPR-Cas9 technology.
During the early years of operation, key challenges included scientific validation of the technology, intellectual property protection, capital raising, and the structuring of robust clinical pipelines. Early achievements included preclinical advances and the initiation of translational research programs.
Expansion and growth occurred through the progression of clinical programs, the formation of strategic partnerships with pharmaceutical companies, and the broadening of genome editing applications into new therapeutic areas, including oncology and immunology.
Historical milestones include the completion of the initial public offering (IPO) in 2016 on the Nasdaq, which enabled access to capital to accelerate clinical development, as well as the initiation of human clinical trials for hematological diseases in subsequent years.
Between 2020 and 2024, relevant developments included progress in gene therapy clinical studies, regulatory submissions across multiple jurisdictions, advanced-stage clinical trial results, strategic adjustments to the research portfolio, and share price volatility influenced by scientific milestones and broader biotechnology market conditions.
Additional Information
The Company CRISPR Therapeutics AG (United States), is listed on Nasdaq with a market value of $ 5.05 Billions, having an equity of $ 1.92 Billion.
With a total of 93 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 35.00 Millions, which generated a loss in the amount of $ -488.30 Millions.
As for its main indicators, the Company has a P/E ratio of -10.35, a P/BV ratio of 2.64 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker CRSP.
